Form 4 volume nearly doubled to 1,473 filings in the week of August 3 as trading windows reopened after the July earnings wave, and insider selling climbed to $5.05 billion, the heaviest week since early June. Reported buying more than doubled to $269.4 million, but about 74% of it arrived at prices fixed in advance, led by a $159.0 million Braveheart Bio financing reported on Form 4. Strip the fixed-price money out and the conviction list is short, headed by Boston Scientific’s chief executive paying $9.0 million on the open market.
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules